Skip to main content
Carisma Therapeutics Inc. logo

Carisma Therapeutics Inc. — Investor Relations & Filings

Ticker · CARM ISIN · US14216R1014 LEI · 549300DGKHONOZQIY116 US Manufacturing
Open in API
Filings indexed 853 across all filing types
Latest filing 2023-06-09 Director's Dealing
Country US United States of America
Listing US CARM

About Carisma Therapeutics Inc.

https://sesenbio.com/

Carisma Therapeutics Inc. is a clinical-stage biotechnology company pioneering the development of engineered macrophage-based therapeutics. The company's proprietary cell therapy platform is centered on Chimeric Antigen Receptor Macrophages (CAR-M) and CAR-Monocytes. This approach is designed to leverage the unique abilities of macrophages to infiltrate solid tumors, overcome the immunosuppressive tumor microenvironment, and stimulate a broad anti-tumor response. Carisma's pipeline is focused on developing treatments for cancer and other serious disorders, including fibrosis.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2023-06-09 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-06-09 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-06-09 English
Regulatory Filings 2023
Regulatory Filings
2023-05-16 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 12, 2023, by Carisma Therapeutics Inc. It reports the entry into a material definitive agreement, specifically an Amended and Restated Open Market Sale Agreement with Jefferies LLC for the sale of common stock. The document includes details about the agreement, the prospectus supplement, and related legal opinions. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The content focuses on a capital raising activity through an at-the-market offering. Therefore, this filing is best classified as a Capital/Financing Update (CAP). The document length (7057 characters) supports it being a substantive filing rather than a brief announcement. Confidence is high given the clear description of the financing agreement and related details.
2023-05-12 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a registration statement for an at-the-market offering of common stock. It includes detailed information about the offering, the sales agreement with Jefferies LLC, risk factors, use of proceeds, dilution, and plan of distribution. The document is not a financial report, earnings release, or management discussion but rather a capital raising disclosure document. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and financing activities.
2023-05-12 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.